Single-use lower agitation type bioreactor. Suitable for suspension cell culture applications. High stirring capability! Safe at a total height of under 3m even for 2,000L.
The Allegro(TM) STR single-use bioreactor achieves high mixing capabilities and a low overall height of less than 3 meters, even with a capacity of 2,000 L, thanks to its rectangular culture vessel, which surpasses the performance of traditional cylindrical culture vessels. ■ High Mixing Capability The effective baffle effect of the rectangular culture vessel and the elephant ear-shaped mixing blades allow for the desired oxygen transfer rate to be achieved at lower stirring speeds than before. This results in high kLa and P/V values, reducing shear stress on cells during cultivation at lower stirring speeds. ■ Geometric Similarity Across All Scales, Including Mixing Blades Maintains a similar shape across all scales of 50, 200 L, 500 L, 1,000 L, and 2,000 L. ■ Scalable with Constant P/V Due to geometric similarity and the ability to achieve high P/V values, scaling up with constant P/V is possible. ■ Overall Height Below 3 M Even at 2,000 L Significantly reduces the need for high-altitude work, ensuring the safety of operators. ■ Easy Installation of Dedicated Culture Bags After transporting the single-use culture bag into the culture vessel, it can be set up within 30 minutes with minimal operator intervention.
Inquire About This Product
basic information
【Lineup】50 L, 200 L, 500 L, 1,000 L, 2,000 L 【Stirring Method】Lower stirring by an elephant ear type direct drive impeller 【Maximum kLa】40 /h 【Stirring Performance】Time required to achieve uniformity in the tank is less than 30 seconds at each scale 【Scalability of Cell Proliferation】Scalability data available from bench-top jar fermenters (CHO cells) *For each data point, please download the PDF or contact us for more details.
Price range
Delivery Time
Applications/Examples of results
【Examples of Use】 ■ Production of viral vectors for gene therapy and vaccines using suspension cell culture with HEK293 cells, etc. ■ Production of baculoviruses for gene therapy using insect cell culture with Sf9 cells, etc. ■ Production of monoclonal antibodies using suspension cell culture with CHO cells, etc. ■ Production of viral vectors for gene therapy and vaccines using adherent cell culture with VERO cells on microcarriers, etc.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
